Holen Sie sich die Stockscreener-App
97.85
1.17%
1.13
Handel nachbörslich:
97.85
Schlusskurs vom Vortag:
$96.72
Offen:
$95.12
24-Stunden-Volumen:
4.53M
Relative Volume:
1.43
Marktkapitalisierung:
$21.21B
Einnahmen:
$819.56M
Nettoeinkommen (Verlust:
$-1.18B
KGV:
-17.04
EPS:
-5.7434
Netto-Cashflow:
$-951.64M
1W Leistung:
+3.85%
1M Leistung:
-15.65%
6M Leistung:
-50.33%
1J Leistung:
+1.00%
1-Tages-Spanne:
$93.92
$98.51
1-Wochen-Bereich:
$90.39
$99.55
52-Wochen-Spanne:
$90.39
$212.75
Insmed Inc Stock (INSM) Company Profile
Firmenname
Insmed Inc
Sektor
Branche
Telefon
908-977-9900
Adresse
700 US HIGHWAY 202/206, BRIDGEWATER, NJ
Compare INSM vs VRTX, REGN, ARGX, ALNY, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
INSM
Insmed Inc
|
97.85 | 21.21B | 819.56M | -1.18B | -951.64M | -5.7434 |
VRTX
Vertex Pharmaceuticals Inc
|
444.93 | 112.92B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
612.14 | 64.18B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
893.52 | 55.57B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
282.85 | 37.76B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
153.87 | 32.71B | 742.00K | -1.37B | -1.07B | -7.0731 |
Insmed Inc Stock (INSM) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-04-10 | Eingeleitet | Raymond James | Outperform |
| 2026-03-30 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2026-03-16 | Fortgesetzt | Jefferies | Buy |
| 2026-01-28 | Eingeleitet | Barclays | Overweight |
| 2026-01-23 | Eingeleitet | Roth Capital | Buy |
| 2025-12-19 | Fortgesetzt | Truist | Buy |
| 2025-12-04 | Eingeleitet | Rothschild & Co Redburn | Buy |
| 2025-10-28 | Fortgesetzt | Cantor Fitzgerald | Overweight |
| 2025-10-20 | Eingeleitet | Wells Fargo | Overweight |
| 2025-08-20 | Eingeleitet | William Blair | Outperform |
| 2025-08-13 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2025-05-13 | Eingeleitet | Jefferies | Buy |
| 2025-02-25 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2024-04-23 | Eingeleitet | Truist | Buy |
| 2024-02-15 | Eingeleitet | Wolfe Research | Outperform |
| 2023-12-08 | Eingeleitet | Wells Fargo | Overweight |
| 2023-11-20 | Fortgesetzt | JP Morgan | Overweight |
| 2023-07-26 | Eingeleitet | Guggenheim | Buy |
| 2022-12-09 | Eingeleitet | Mizuho | Buy |
| 2022-12-07 | Eingeleitet | Barclays | Overweight |
| 2022-11-18 | Eingeleitet | BofA Securities | Buy |
| 2022-04-27 | Eingeleitet | Goldman | Buy |
| 2021-12-06 | Eingeleitet | JP Morgan | Overweight |
| 2021-10-19 | Fortgesetzt | Monness Crespi & Hardt | Buy |
| 2021-10-19 | Fortgesetzt | Morgan Stanley | Overweight |
| 2021-10-08 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2021-04-26 | Fortgesetzt | Credit Suisse | Outperform |
| 2020-12-17 | Eingeleitet | Berenberg | Buy |
| 2020-10-12 | Fortgesetzt | Stifel | Buy |
| 2019-09-03 | Eingeleitet | Goldman | Buy |
| 2019-04-09 | Bestätigt | H.C. Wainwright | Buy |
| 2019-02-15 | Hochstufung | JMP Securities | Mkt Perform → Mkt Outperform |
| 2019-01-17 | Hochstufung | Goldman | Neutral → Buy |
| 2019-01-02 | Eingeleitet | Canaccord Genuity | Buy |
| 2018-08-06 | Herabstufung | JMP Securities | Mkt Outperform → Mkt Perform |
| 2018-07-23 | Eingeleitet | Goldman | Neutral |
| 2018-04-23 | Hochstufung | Credit Suisse | Neutral → Outperform |
| 2018-03-21 | Eingeleitet | Morgan Stanley | Overweight |
| 2018-01-18 | Eingeleitet | Credit Suisse | Neutral |
| 2017-09-05 | Bestätigt | Evercore ISI | Outperform |
| 2017-08-17 | Eingeleitet | Evercore ISI | Outperform |
| 2017-07-11 | Eingeleitet | Robert W. Baird | Outperform |
| 2016-03-15 | Eingeleitet | Stifel | Buy |
| 2015-11-09 | Herabstufung | UBS | Buy → Neutral |
| 2015-10-06 | Bestätigt | H.C. Wainwright | Buy |
| 2015-06-09 | Eingeleitet | Citigroup | Neutral |
| 2014-03-26 | Bestätigt | HC Wainwright | Buy |
Alle ansehen
Insmed Inc Aktie (INSM) Neueste Nachrichten
Monashee Investment Management LLC Acquires Shares of 50,000 Insmed, Inc. $INSM - MarketBeat
A Blueprint For Addressing Underserved Patient Populations - Clinical Leader
Nasdaq-100 Index® June 2026 Quarterly Changes - GlobeNewswire Inc.
INSM Stock Dips In Extended Trading After Experimental Skin Disease Drug Fails In Study - Stocktwits
BofA Securities Maintains Insmed(INSM.US) With Buy Rating, Maintains Target Price $214 - Moomoo
Insmed stock hits 52-week low at 90.85 USD By Investing.com - Investing.com Nigeria
Daily Brief Health Care: Laurus Labs, Ascendis Pharma, GSK , Incyte Corp, Insmed Inc, Johnson & Johnson, Kardigan, LogicMark, Parabilis Medicines, Solventum and more - Smartkarma
Insmed slides 7.9% as risk-off tape collides with pipeline-focused positioning ahead of TPIP data - Quiver Quantitative
[Form 4] INSMED Inc Insider Trading Activity - Stock Titan
Insmed stock hits 52-week low at 90.85 USD - Investing.com
Stock Traders Purchase High Volume of Call Options on Insmed (NASDAQ:INSM) - MarketBeat
Cantor Fitzgerald reiterates Insmed stock rating on TPIP data outlook - Investing.com UK
Cantor Fitzgerald reiterates Insmed stock rating on TPIP data outlook By Investing.com - Investing.com Australia
GW&K Investment Management LLC Reduces Position in Insmed, Inc. $INSM - MarketBeat
Axiom Investors LLC DE Has $44.53 Million Position in Insmed, Inc. $INSM - MarketBeat
Insmed Inc stock (US4576693075): pipeline update and growth story in rare diseases - AD HOC NEWS
INSM: Brensocatib’s stellar launch and expanding pipeline set the stage for sustained growth - TradingView
Insmed Inc at Goldman Sachs Healthcare Conference Transcript - GuruFocus
INSM Maintained by JP Morgan -- Price Target Lowered to $179 - GuruFocus
Insmed (INSM) Remains a Strong Buy Despite Recent Stock Decline - GuruFocus
William Lewis files Form 144 — INSM insider sale notice (INSM) - Stock Titan
Insmed’s New Lung Disease Study Data A Win For Company, Says Analyst - Stocktwits
JPMorgan Chase & Co. Cuts Insmed (NASDAQ:INSM) Price Target to $179.00 - MarketBeat
Is Insmed (INSM) The Best Healthcare Stock to Buy Now? - Yahoo Finance
Roth MKM Maintains Insmed(INSM.US) With Buy Rating, Maintains Target Price $212 - Moomoo
ING Groep NV Sells 250,555 Shares of Insmed, Inc. $INSM - MarketBeat
Fiera Capital Corp Raises Stock Position in Insmed, Inc. $INSM - MarketBeat
Clearbridge Investments LLC Has $142.54 Million Stock Holdings in Insmed, Inc. $INSM - MarketBeat
Daiwa Securities Group Inc. Acquires 34,648 Shares of Insmed, Inc. $INSM - MarketBeat
Fjarde AP Fonden Fourth Swedish National Pension Fund Purchases Shares of 50,500 Insmed, Inc. $INSM - MarketBeat
INSM, FSLR, APTV: Dreaded Death Cross Has Formed On These Stocks — What It Means For Investors - Stocktwits
Operating income of Insmed Incorporated – XETR:IM8N - TradingView
Return on equity % of Insmed Incorporated – XETR:IM8N - TradingView
Insmed Incorporated Balance Sheet – XETR:IM8N - TradingView
Is Insmed's (INSM) Brensocatib Momentum Quietly Reframing Its Respiratory Growth Narrative? - Yahoo Finance
Harvest Fund Management Co. Ltd Acquires 14,454 Shares of Insmed, Inc. $INSM - MarketBeat
INSM Maintained by RBC Capital -- Price Target Lowered to $195 - GuruFocus
INSM: Director Martina Flammer reports multiple Rule 144 sales (INSM) - Stock Titan
Insmed Chair, CEO Sold Shares Worth Over $777K - TradingView
INSMED (INSM) COO sells 2,370 shares to cover RSU tax withholding - Stock Titan
Insmed (NASDAQ: INSM) CFO sells 2,404 shares to cover RSU taxes - Stock Titan
INSMED (INSM) legal chief sells 2,159 shares to cover RSU tax - Stock Titan
Insmed (INSM) CMO sells 4,424 shares for tax withholding under plan - Stock Titan
Insmed Brinsupri Shows Strong Physician Conviction, Early Launch Momentum, RBC Says - Moomoo
RBC Capital Adjusts Insmed Price Target to $195 From $205, Maintains Outperform Rating - Moomoo
RBC Capital lowers Insmed stock price target to $195 on model refinement - Investing.com UK
Insmed Reports Inducement Grants under NASDAQ Listing Rule 5635(4) - marketscreener.com
RBC Capital lowers Insmed stock price target to $195 on model refinement By Investing.com - Investing.com South Africa
Insmed earnings up next: Can Brinsupri sustain blockbuster launch? By Investing.com - Investing.com Nigeria
UBS Maintains Insmed(INSM.US) With Buy Rating, Maintains Target Price $166 - Moomoo
Insmed (INSM) Grants Equity Awards to New Employees Amid Growth Phase - GuruFocus
Finanzdaten der Insmed Inc-Aktie (INSM)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.04%
0.76%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):